Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. 

Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Biotechnology

Clinical Trials

Life Sciences

Therapeutics

Convergent Therapeutics, Inc.

Convergent Therapeutics, Inc.'s headquarters in Cambridge, United States

Philip Kantoff

Danielle Quarles

Scott Myers

Caitlyn Harvey

Eric Sullivan

Convergent Therapeutics, Inc.

Org chart

Teams

Offices

Similar companies